Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase*

The compound U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay. U0126 was also shown to inhibit endogenous promoters containing AP-1 response elements but did not affect genes lacking an AP-1 response element in their promoters. These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2. Inhibition is selective for MEK-1 and -2, as U0126 shows little, if any, effect on the kinase activities of protein kinase C, Abl, Raf, MEKK, ERK, JNK, MKK-3, MKK-4/SEK, MKK-6, Cdk2, or Cdk4. Comparative kinetic analysis of U0126 and the MEK inhibitor PD098059 (Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 7686–7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK. We further demonstrate that the two compounds bind to ΔN3-S218E/S222D MEK in a mutually exclusive fashion, suggesting that they may share a common or overlapping binding site(s). Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for ΔN3-S218E/S222D MEK than does PD098059. We further tested the effects of these compounds on the activity of wild type MEK isolated after activation from stimulated cells. Surprisingly, we observe a significant diminution in affinity of both compounds for wild type MEK as compared with the ΔN3-S218E/S222D mutant enzyme. These results suggest that the affinity of both compounds is mediated by subtle conformational differences between the two activated MEK forms. The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.

[1]  R. Brattsand,et al.  Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. , 1996, Alimentary pharmacology & therapeutics.

[2]  P. Herrlich,et al.  Mutual cross-modulation of steroid/retinoic acid receptor and AP-1 transcription factor activities A novel property with practical implications , 1994, Trends in Endocrinology & Metabolism.

[3]  C. Widmann,et al.  MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? , 1997, Current opinion in genetics & development.

[4]  K. Guan,et al.  Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. , 1993, The Journal of biological chemistry.

[5]  M. Cobb,et al.  Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs. , 1992, Biochemical and biophysical research communications.

[6]  L. G. Davis,et al.  Basic methods in molecular biology , 1986 .

[7]  L. G. Davis,et al.  Formaldehyde Gel for Electrophoretic Separation of RNA and Northern Blot , 1986 .

[8]  A. Cato,et al.  Molecular mechanisms of anti‐inflammatory action of glucocorticoids , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  P. Cuatrecasas,et al.  Mitogen-activated Protein Kinase Kinase Inhibition Does Not Block the Stimulation of Glucose Utilization by Insulin (*) , 1995, The Journal of Biological Chemistry.

[10]  C. Brinckerhoff,et al.  Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. , 1996, Critical reviews in eukaryotic gene expression.

[11]  S. Meloche,et al.  Inhibition of Growth Factor-induced Protein Synthesis by a Selective MEK Inhibitor in Aortic Smooth Muscle Cells* , 1996, The Journal of Biological Chemistry.

[12]  J. Brown,et al.  Dissociation of p44 and p42 Mitogen-activated Protein Kinase Activation from Receptor-induced Hypertrophy in Neonatal Rat Ventricular Myocytes (*) , 1996, The Journal of Biological Chemistry.

[13]  G. Nicolson,et al.  Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. , 1996, Cancer research.

[14]  K. Malarkey,et al.  The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. , 1995, The Biochemical journal.

[15]  W. Middleton,et al.  Cyanocarbon Chemistry. III.1 Addition Reactions of Tetracyanoethylene , 1958 .

[16]  A. Fauci,et al.  Mechanisms of glucocorticoid action on immune processes. , 1979, Annual review of pharmacology and toxicology.

[17]  E. Fleck,et al.  Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. , 1997, Hypertension.

[18]  S. Watson,et al.  Inhibition of mitogen-activated protein kinase kinase does not impair primary activation of human platelets. , 1996, The Biochemical journal.

[19]  D. Granner,et al.  [80] Tyrosine aminotransferase (rat liver)☆☆☆ , 1970 .

[20]  N. Ahn,et al.  Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.

[21]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Fuller,et al.  The steroid receptor superfamily: mechanisms of diversity , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Schroen Dj,et al.  Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. , 1996 .

[24]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[25]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[26]  A. Depaoli-Roach,et al.  Regulation of Both Glycogen Synthase and PHAS-I by Insulin in Rat Skeletal Muscle Involves Mitogen-activated Protein Kinase-independent and Rapamycin-sensitive Pathways (*) , 1996, The Journal of Biological Chemistry.

[27]  U. Gehring Steroid hormone receptors: biochemistry, genetics, and molecular biology , 1987 .

[28]  G. Firestone,et al.  Glucocorticoid receptor-dependent inhibition of cellular proliferation in dexamethasone-resistant and hypersensitive rat hepatoma cell variants. , 1988, Molecular and cellular biology.

[29]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[30]  W. DeGrado,et al.  Design of DNA-binding peptides based on the leucine zipper motif. , 1990, Science.

[31]  J. Avruch,et al.  Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation* , 1996, The Journal of Biological Chemistry.

[32]  D. Burt,et al.  Identification of negative and positive regulatory elements in the human renin gene. , 1989, The Journal of biological chemistry.

[33]  E. Hu,et al.  Targeted disruption of the c‐fos gene demonstrates c‐fos‐dependent and ‐independent pathways for gene expression stimulated by growth factors or oncogenes. , 1994, The EMBO journal.

[34]  W. Middleton,et al.  Cyanocarbon Chemistry. VIII.1 Heterocyclic Compounds from Tetracyanoethylene , 1958 .

[35]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[36]  J. O'flaherty,et al.  Differential effects of a mitogen-activated protein kinase kinase inhibitor on human neutrophil responses to chemotactic factors. , 1997, Biochemical and biophysical research communications.

[37]  S. Freguia PROTEINS AND ENZYMES , 1955 .

[38]  F. McCormick,et al.  Signal transduction from multiple Ras effectors. , 1997, Current opinion in genetics & development.

[39]  F. Dumont,et al.  Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. , 1998, Journal of immunology.

[40]  M. May,et al.  Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI2 release but has no effect on von Willebrand factor secretion or E‐selectin expression , 1996, FEBS letters.

[41]  G. Ringold Steroid hormone regulation of gene expression. , 1985, Annual review of pharmacology and toxicology.

[42]  P. Chambon,et al.  RAR‐specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage‐independent cell proliferation. , 1995, The EMBO journal.

[43]  R. Davis,et al.  The mitogen-activated protein kinase signal transduction pathway. , 1993, The Journal of biological chemistry.

[44]  C. Leslie Properties and Regulation of Cytosolic Phospholipase A2 * , 1997, The Journal of Biological Chemistry.